252 related articles for article (PubMed ID: 20063259)
1. Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Giese A; Bock HC; Kantelhardt SR; Rohde V
Cent Eur Neurosurg; 2010 Nov; 71(4):199-206. PubMed ID: 20063259
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
3. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
[TBL] [Abstract][Full Text] [Related]
4. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Nagpal S
Neurosurg Clin N Am; 2012 Apr; 23(2):289-95, ix. PubMed ID: 22440872
[TBL] [Abstract][Full Text] [Related]
5. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
[TBL] [Abstract][Full Text] [Related]
6. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
[TBL] [Abstract][Full Text] [Related]
7. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Sabel M; Giese A
Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M;
Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Olivi A; Grossman SA; Tatter S; Barker F; Judy K; Olsen J; Bruce J; Hilt D; Fisher J; Piantadosi S;
J Clin Oncol; 2003 May; 21(9):1845-9. PubMed ID: 12721262
[TBL] [Abstract][Full Text] [Related]
11. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Murai S; Ichikawa T; Kurozumi K; Shimazu Y; Oka T; Otani Y; Shimizu T; Date I
J Clin Neurosci; 2016 Nov; 33():148-153. PubMed ID: 27452129
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
[TBL] [Abstract][Full Text] [Related]
14. [Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Ishikawa E; Yamamoto T
Gan To Kagaku Ryoho; 2016 May; 43(5):603-7. PubMed ID: 27210091
[TBL] [Abstract][Full Text] [Related]
15. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Kosteljanetz M; Poulsen HS
Ugeskr Laeger; 2010 Jan; 172(3):214-7. PubMed ID: 20089214
[TBL] [Abstract][Full Text] [Related]
17. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
[TBL] [Abstract][Full Text] [Related]
18. Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Dörner L; Mustafa A; Rohr A; Mehdorn HM; Nabavi A
J Clin Neurosci; 2013 Mar; 20(3):429-34. PubMed ID: 23313517
[TBL] [Abstract][Full Text] [Related]
19. Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Asano K; Kurose A; Kamataki A; Kato N; Ogawa K; Katayama K; Kakuta K; Fumoto T; Ohkuma H
Brain Tumor Pathol; 2018 Jul; 35(3):131-140. PubMed ID: 29948295
[TBL] [Abstract][Full Text] [Related]
20. Polymeric drug delivery for the treatment of glioblastoma.
Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
